Eric Hsu - InMed Pharmaceuticals Senior Development
| INM Stock | USD 3.16 0.06 1.94% |
Executive
Eric Hsu is Senior Development of InMed Pharmaceuticals
| Age | 55 |
| Phone | 604 669 7207 |
| Web | https://www.inmedpharma.com |
Eric Hsu Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eric Hsu against InMed Pharmaceuticals stock is an integral part of due diligence when investing in InMed Pharmaceuticals. Eric Hsu insider activity provides valuable insight into whether InMed Pharmaceuticals is net buyers or sellers over its current business cycle. Note, InMed Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell InMed Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eric Hsu over six months ago Disposition of 327 shares by Eric Hsu of InMed Pharmaceuticals at 499.96 subject to Rule 16b-3 | ||
Eric Hsu over six months ago Acquisition by Eric Hsu of 45000 shares of InMed Pharmaceuticals at 0.37 subject to Rule 16b-3 | ||
Eric Hsu over six months ago Disposition of 309 shares by Eric Hsu of InMed Pharmaceuticals at 364.72 subject to Rule 16b-3 | ||
Eric Hsu over a year ago Expiration or cancellation by Eric Hsu of long derivative position of 327 shares of InMed Pharmaceuticals |
InMed Pharmaceuticals Management Efficiency
The company has Return on Asset of (0.4086) % which means that on every $100 spent on assets, it lost $0.4086. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.835) %, meaning that it generated no profit with money invested by stockholders. InMed Pharmaceuticals' management efficiency ratios could be used to measure how well InMed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jose MD | Allarity Therapeutics | 68 | |
| Alexander Epshinsky | Allarity Therapeutics | 42 | |
| Tim Varacek | LMF Acquisition Opportunities | N/A | |
| Joel Yeung | Virax Biolabs Group | N/A | |
| Ben JD | Immix Biopharma | N/A | |
| Tom Mullen | LMF Acquisition Opportunities | N/A | |
| Dr MBA | Tonix Pharmaceuticals Holding | 66 | |
| MD FFPM | Immix Biopharma | 65 | |
| James MBA | Tonix Pharmaceuticals Holding | N/A | |
| CPI FACOG | Biodexa Pharmaceticals | 71 | |
| Daniel MBA | Biodexa Pharmaceticals | N/A | |
| Sina Bavari | Tonix Pharmaceuticals Holding | N/A | |
| Alexander CPA | Allarity Therapeutics | 41 | |
| Joerg Heyer | Palisade Bio | N/A | |
| Tommy Law | NovaBay Pharmaceuticals | 40 | |
| Sai Iyer | LMF Acquisition Opportunities | N/A | |
| Lily Fu | Virax Biolabs Group | N/A | |
| Stephen McAndrew | Sonnet Biotherapeutics Holdings | 71 | |
| Dmitry MD | Biodexa Pharmaceticals | 44 | |
| Mitchell MD | Palisade Bio | 47 | |
| Ryker Willie | Palisade Bio | N/A | |
Management Performance
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.41 |
InMed Pharmaceuticals Leadership Team
Elected by the shareholders, the InMed Pharmaceuticals' board of directors comprises two types of representatives: InMed Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InMed. The board's role is to monitor InMed Pharmaceuticals' management team and ensure that shareholders' interests are well served. InMed Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InMed Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sazzad MSc, CoFounder | ||
| MIB Chem, CEO President | ||
| Ado Muhammad, Consultant Affairs | ||
| Colin Clancy, Director Relations | ||
| Eric Hsu, Senior Development | ||
| Netta Jagpal, CFO Secretary | ||
| Jerry Griffin, Vice Marketing | ||
| Jonathan Tegge, Interim Officer | ||
| Michael PEng, Chief Officer | ||
| Shane Johnson, Senior BayMedica | ||
| CGA CPA, Controller Accounting | ||
| Alexandra MSc, Senior Affairs |
InMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is InMed Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.41 | ||||
| Profit Margin | (1.64) % | ||||
| Operating Margin | (1.98) % | ||||
| Current Valuation | (2.24 M) | ||||
| Shares Outstanding | 724.15 K | ||||
| Shares Owned By Insiders | 0.34 % | ||||
| Shares Owned By Institutions | 13.70 % | ||||
| Number Of Shares Shorted | 33.07 K | ||||
| Price To Book | 0.27 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.